CBT Pharmaceuticals

CBT Pharmaceuticals creates scientific advisory board

Monday, August 28, 2017

CBT Pharmaceuticals, a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer,  announced the appointments of Robert A. Figlin, M.D., FACP and Frank McCormick, Ph.D., FRS, DSc. to its newly established Scientific Advisory Board (SAB).

[Read More]